Zydus Pharmaceuticals
Zydus Pharmaceuticals, a prominent player in the global pharmaceutical industry, is headquartered in the United States, with significant operations across North America, Europe, and Asia. Founded in 1995, the company has established itself as a leader in the development and manufacturing of generic and specialty pharmaceuticals, focusing on areas such as oncology, cardiovascular health, and diabetes management. Zydus Pharmaceuticals is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that includes injectables, biosimilars, and over-the-counter medications. The company has achieved notable milestones, including numerous FDA approvals and a strong presence in the biosimilars market, positioning it as a trusted name in healthcare. With a dedication to improving patient outcomes, Zydus continues to expand its reach and impact within the pharmaceutical landscape.
DitchCarbon Score
How does Zydus Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zydus Pharmaceuticals's score of 10 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Zydus Pharmaceuticals's reported carbon emissions
In 2023, Zydus Pharmaceuticals reported total carbon emissions of approximately 6,650,000 kg CO2e for Scope 1 and about 8,969,000 kg CO2e for Scope 2. This indicates a significant reduction in emissions compared to 2024, where Scope 1 emissions were approximately 31,304,000 kg CO2e, while Scope 2 emissions were about 8,798,000 kg CO2e. Despite these figures, Zydus Pharmaceuticals has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The absence of formal commitments suggests that while the company is actively monitoring its emissions, it may not yet have established a comprehensive strategy for long-term carbon reduction. Overall, Zydus Pharmaceuticals is navigating the complexities of carbon emissions management within the pharmaceutical industry, focusing on transparency in its reporting while potentially exploring future climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 6,650,000 | 00,000,000 |
| Scope 2 | 8,969,000 | 0,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zydus Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
